"There may be explanations for such repeated, vast discrepancies between the total numbers of patents and exclusivity periods reported by I-MAK and the official data on the patents covering these drugs that are found in governmental sources such as the FDA's Orange Book or court opinions. Still, these are substantial discrepancies in total numbers of patents."
"I-MAK's view is that the U.S. patent system creates patent monopolies that lead to the practice of 'evergreening', in which innovator pharmaceutical companies extend their rights beyond the original patent terms, preventing competition from generics, which in turn causes drug prices to remain high."
A Policy Memo from the Hudson Institute claims that key data used in discussions about pharmaceutical patents and their impact on drug pricing may be unreliable. The memo criticizes the Initiative for Medicines, Access & Knowledge (I-MAK) for its data on patents and patent applications. I-MAK argues that the U.S. patent system fosters monopolies and 'evergreening', which hinders competition and keeps drug prices high. Mossoff's memo highlights significant discrepancies in patent numbers reported by I-MAK compared to official sources.
Read at IPWatchdog.com | Patents & Intellectual Property Law
Unable to calculate read time
Collection
[
|
...
]